Abstract:The pathogenesis of Alzheimer's disease (AD) remains elusive. Brain glucose hypometabolism, an invariant feature, precedes and closely correlates with clinical symptoms and signs in AD. To clarify the mechanism of cerebral glucose metabolism will help to understand AD pathogenesis. Cerebral glucose metabolism was evaluated by FDG-PET in AD patients and the mice with thiamine deficiency (TD) by diet deprivation. Brain amyloid deposit was measured by PiB-PET. Thiamine diphosphate (TDP), thiamine monophosphate, and thiamine levels were detected by high performance liquid chromatography. The diagnostic value of blood TDP level for AD was analyzed. The effects of thiamine metabolism on dendrtic branching, spine, and soma size of enurons were investigated by inhibiting thiamine pyrophosphokinase (TPK), the key enzyme of thiamine metabolism, and transporters (SLC19A2, SLC19A3, SLC25A19) via TPK antagonist (pyrithiamine) and/or RNA interference. Blood TDP level in AD patients and blood and brain TDP levels in TD mice were significantly reduced as compared with that in control groups (n=1199 for human subjects and n=6 for mice), patients with vascular dementia (n=67) and frontotemporal dementia (n=13, all P<0.001). Blood TDP level in AD patients (n=14) and blood/brain TDP levels in TD mice (n=6) was closely correlated with glucose metabolism of cotices examined. Blood TDP level exhibited a promising value for AD diagnosis (0.830 of AUC, 76.5% of sensititvity, and 77.5% of specificity) and differential diagnosis from vascular dementia and frontotemporal dementia. Brain amyloid deposit in AD patients was not significantly correlated with blood TDP level (n=32). Pyrithiamine and RNA interference against TPK and transporters (SLC19A2, SLC19A3, SLC25A19) significantly reduced dendritic brainching, spine density, and soma size of neurons (n=9-64 in 3 batches of cultured hippocampal neurons). The disruption of thiamie metabolism in AD contributes to brain glucose hypometabolism and neurodegeneration. Combinging with the previous studies, we propose that AD is a metabolic disorder and hypothesize that disrutped thiamiine metabolism directly contributes to AD pathogenesis by perturbing glucose utilization and inducing multiple pathogenic factors in the brain. Altered thiamine metabolism is a useful diagnostic biomarker for AD and a potential target for the disease-modifying study.

Powerful Beneficial Effects of Benfotiamine on Cognitive Impairment and Beta-Amyloid Deposition in Amyloid Precursor Protein/Presenilin-1 Transgenic Mice

Long-Term Cognitive Improvement after Benfotiamine Administration in Patients with Alzheimer'S Disease

BENFOTIAMINE IMPROVES COGNITIVE ABILITY OF ALZHEIMER’S PATIENTS INDEPENDENT OF AMYLOID DEPOSITION

Nicotinamide Forestalls Pathology and Cognitive Decline in Alzheimer Mice: Evidence for Improved Neuronal Bioenergetics and Autophagy Procession

Metformin Treatment Attenuates Tau Seeding in Neuritic Plaques

The Influence for Senile Rats Learning and Memory Ability of Benfotiamine

Efficacy of benfotiamine plus donepezil treatment for patients with mild‐to‐moderate Alzheimer’s disease: multicenter, randomized, phase II clinical trial

Metformin Attenuates Plaque-Associated Tau Pathology and Reduces Amyloid-Β Burden in APP/PS1 Mice

Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice.

Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-α

Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer's disease mouse model and proteomics analysis

Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of β-amyloid in APP/tau/PS1 mouse model of Alzheimer's disease

Berberine Improves Cognitive Impairment by Simultaneously Impacting Cerebral Blood Flow and Β-Amyloid Accumulation in an APP/tau/PS1 Mouse Model of Alzheimer's Disease.

Thamnolia Vermicularis Extract Improves Learning Ability in APP/PS1 Transgenic Mice by Ameliorating Both Aβ and Tau Pathologies

Thiamine Diphosphate Reduction Strongly Correlates with Brain Glucose Hypometabolism in Alzheimer’s Disease, Whereas Amyloid Deposition Does Not

Thiamine Deficiency Induced β-amyloid Deposition and Tau Hyperphosphorylation

BHBA treatment improves cognitive function by targeting pleiotropic mechanisms in transgenic mouse model of Alzheimer's disease

Benfotiamine Prevents Increased Β-Amyloid Production in HEK Cells Induced by High Glucose

P1‐078: Reduced Thiamine Diphosphate Level Contributes to Brain Glucose Hypometabolism and Neurodegeneration in Alzheimer's Disease

Thiamine pyrophosphokinase-1 deficiency in neurons drives Alzheimer's multiple pathophysiological alterations

The Impact of Thiamine Deficiency and Benfotiamine Treatment on Nod-like Receptor Protein-3 Inflammasome in Microglia.